Safety and efficacy comparison of remimazolam and propofol for intravenous anesthesia during gastroenteroscopic surgery of older patients: A meta-analysis

Table 1 The characteristics of included studies

Ref.		Age (yr)	Gender (M/F)	ASA (I/II)	BMI (kg/m2)	No. of patients
Ye et al[20], 2023	Remimazolam	68. 67 ± 4.55	39/25	44/64	NM	64
	Propofol	68. 67 ± 4.55	36/29	48/65	NM	65
Tan et al[21], 2021	Remimazolam	66.4 ± 4.8	19/14	18/15	22.7 ± 3.0	33
	Propofol	66.2 ± 5.0	21/12	18/15	23.2 ± 3.0	33
Hu et al[22], 2022	Remimazolam	70.11 ± 7.37	69/104	20/144	22.75 ± 3.15	173
	Propofol	69.92 ± 7.57	72/101	26/140	22.73 ± 3.23	173
Liu et al[23], 2023	Remimazolam	67.5 ± 4.9	51/58	11/96	23.7 ± 3.0	107
	Propofol	67.5 ± 5.7	51/56	10/99	24.0 ± 2.6	109
Guo et al[24], 2022	Remimazolam	70.4 ± 3.9	25/14	7/32	23.0 ± 3.0	38
	Propofol	69.1 ± 4.0	22/16	7/31	23.0 ± 3.4	38
Lu et al[25], 2022	Remimazolam	70.6 ± 4.7	78/122	6/192	22.2 ± 2.5	200
	Propofol	70.1 ± 4.5	83/117	17/181	22.2 ± 2.3	200
Liu et al[26], 2021	Remimazolam	68.87 ± 2.58	54/61	37/78	25.35 ± 2.07	115
	Propofol	69.12 ± 2.75	58/59	46/71	24.75 ± 2.16	117

ASA: American Society of Anesthesiologists Score; BMI: Body mass index; NM: Not mentioned.